Valneva (VALN) has released an update.
Valneva is set to receive up to $41.3 million from CEPI and the EU to enhance access to IXCHIQ®, the world’s first chikungunya vaccine, particularly in low- and middle-income countries. The funding will bolster clinical trials in vulnerable groups and support technology transfer to additional manufacturers, ensuring wider distribution in regions at risk of chikungunya outbreaks. With approvals already in place in the U.S., Canada, and Europe, the company aims to extend the vaccine’s reach to address this growing public health concern.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
